0001570562-24-000017.txt : 20240209 0001570562-24-000017.hdr.sgml : 20240209 20240209183606 ACCESSION NUMBER: 0001570562-24-000017 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240207 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Avelar Rui CENTRAL INDEX KEY: 0001432063 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38381 FILM NUMBER: 24616904 MAIL ADDRESS: STREET 1: 1618 STATION STREET CITY: VANCOUVER STATE: A1 ZIP: V6A 1B6 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evolus, Inc. CENTRAL INDEX KEY: 0001570562 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461385614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 520 NEWPORT CENTER DRIVE STREET 2: SUITE 1200 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 BUSINESS PHONE: (949) 284-4555 MAIL ADDRESS: STREET 1: 520 NEWPORT CENTER DRIVE STREET 2: SUITE 1200 CITY: NEWPORT BEACH STATE: CA ZIP: 92660 4 1 wk-form4_1707521755.xml FORM 4 X0508 4 2024-02-07 0 0001570562 Evolus, Inc. EOLS 0001432063 Avelar Rui 520 NEWPORT CENTER DR. SUITE 1200 NEWPORT BEACH CA 92660 0 1 0 0 See Remarks 0 Common Stock 2024-02-07 4 A 0 35211 0 A 388597 D Performance Restricted Stock Units 2024-02-07 4 A 0 17606 0 A Common Stock 17606 17606 D Stock Option (Right to Buy) 13.15 2024-02-07 4 A 0 47337 0 A 2034-02-07 Common Stock 47337 47337 D Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Each performance-based restricted stock unit (PSU) represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 50% of the PSUs earned will vest on February 7, 2026 and the remaining 50% of the PSUs will vest on February 7, 2027, in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates. The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Chief Medical Officer and Head of Research & Development /s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar 2024-02-09